MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

    J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

    Objective: We are assessing use of pimavanserin (PIM) for treatment of depression in adults with PD. Background: Depression occurs in ~50% of Parkinson’s disease (PD)…
  • 2019 International Congress

    Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA

    L. Pons, C. Vilain, P. Picaut (Cambridge, MA, USA)

    Objective: To evaluate safety and pharmacodynamic (PD) profiles of the first recombinant botulinum toxins (BoNT) serotype E (rBoNT-E) versus abobotulinumtoxinA (aboBoNT-A) in healthy male volunteers.…
  • 2019 International Congress

    Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

    A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

    Objective: To evaluate the impact of baseline OFF-time on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…
  • 2019 International Congress

    An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2

    A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

    Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…
  • 2019 International Congress

    INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease

    J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

    Objective: The objective of the INTREPID clinical trial assessed improvement in motor function and quality of life in patients with advanced, levodopa responsive Parkinson's disease…
  • 2019 International Congress

    Brain MRI-based discrimination between multiple system atrophy type cerebellar from other late onset sporadic cerebellar ataxias: a prospective study with implications for diagnosis criteria

    G. Carré, JL. Dietemann, O. Gebus, S. Montaut, O. Lagha-Boukbiza, T. Wirth, S. Kremer, IJ. Namer, M. Anheim, C. Tranchant (Strasbourg, France)

    Objective: To evaluate, in patients with sporadic late-onset cerebellar ataxia (SLOCA), the discriminative value of each of the magnetic resonance imaging (MRI) features for the…
  • 2019 International Congress

    Normative Reference for Timed Up and Go Test (TUG) in Young Indian Adults- Preliminary Results

    D. Kaur, K. Umakant, T. Aziz, P. Jaiswal, M. Kumari, A. Gupta, G. Kumar (Patna, India)

    Objective: This study investigated the clinical usefulness of the time up and go test in young population and provide a reference range for healthy adults.…
  • 2019 International Congress

    Non-CpG methylation in the FXN gene in patients with Friedreich’s ataxia

    E. Nuzhnyi, N. Abramycheva, M. Ershova, S. Klyushnikov, N. Nikolaeva, S. Illarioshkin, E. Fedotova (Moscow, Russian Federation)

    Objective: To compare methylation profiles of non-CpG sites in the FXNgene in patients with Friedreich’s ataxia (FA), their heterozygous relatives and a healthy control group. Background: FA is…
  • 2019 International Congress

    Alcohol- Induced Cerebellar Ataxia

    B. Zeigelboim, H. Teive, C. Santos Junior, J. Malisky, M. da Rosa, R. Sampaio, M. José (Curitiba, Brazil)

    Objective: To verify vestibulocochlear disorders observed in a case of alcohol-induced cerebellar ataxia. Background: Alcohol-induced cerebellar degeneration is the commonest type of acquired toxic ataxia,…
  • 2019 International Congress

    Sydenham’s chorea: Clinical features and treatment outcome

    S. Pandey, P. Rani (New Delhi, India)

    Objective: To study the clinical features, investigations and treatment outcome in Sydenham’s chorea patients. Background: Sydenham’s chorea is one of the major clinical manifestations of…
  • « Previous Page
  • 1
  • …
  • 68
  • 69
  • 70
  • 71
  • 72
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley